Diamyd Medical
14,32
SEK
-2,59 %
DMYD B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 investor følger denne virksomhed
-2,59%
+9,15%
-4,53%
+20,13%
+117,96%
+106,04%
+27,43%
+96,61%
+374,69%
www.diamyd.com
Diamyd Medical is a diabetes company. The company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.
Omsætning
130 t
EBIT %
-112.746,15 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
DMYD B
Daglig lav / høj pris
14,28 / 15,08
SEK
Markedsværdi
1,49 mia. SEK
Aktieomsætning
2,27 mio. SEK
Volumen
154 t
Seneste videoer
Finanskalender
Generalforsamling
05.12.2024
Delårsrapport
29.01.2025
Delårsrapport
09.04.2025
Delårsrapport
25.06.2025
Årsrapport
08.10.2025
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Avanza Pension | 12,2 % | 9,7 % |
| Bertil Lindkvist | 8,7 % | 6,9 % |
| Nordnet Pension | 5,6 % | 4,4 % |
| Anders Essen-Möller | 3,9 % | 9,0 % |
| Maria-Teresa Essen-Möller | 1,4 % | 4,0 % |
| Konstruktions o Försäljningsaktiebolag | 0,9 % | 0,7 % |
| Essen-Möller, Martin | 0,8 % | 3,5 % |
| Essen-Möller, Jon | 0,7 % | 3,7 % |
| Hillborg, Erika | 0,6 % | 3,7 % |
| Essenshaw, My | 0,5 % | 3,2 % |
ViserAlle indholdstyper
Diamyd Medical AB: Article published by ASSET, coordinated by Diamyd Medical, advocates for national screening programs in Sweden for early detection of Type 1 Diabetes
Diamyd Medical AB: Diamyd Medical hits a recruitment milestone in DIAGNODE-3 Phase 3 trial
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools